Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

Oct 3, 2023

A study comparing Rituximab and Ocrelizumab in Relapsing-Remitting Multiple Sclerosis reveals differences in relapse rates but no difference in disability accumulation, emphasizing the need for further research.

Ask episode